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Abstract: Immediate breast reconstruction (IBR) rates after mastectomy 
are increasing. Postmastectomy radiation therapy (PMRT) contouring 
guidelines for target volumes in the setting of IBR are lacking. 
Therefore, many patients who have had IBR receive PMRT to target volumes 
similar to conventional simulator-based whole breast irradiation. The aim 
of this paper is to describe delineation guidelines for PMRT after 
implant-based IBR based on a thorough understanding of the surgical 
procedures, disease stage, patterns of recurrence and radiation 
techniques. They are based on a consensus endorsed by a global 
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Immediate breast reconstruction (IBR) rates after mastectomy are increasing. Postmastectomy 
radiation therapy (PMRT) contouring guidelines for target volumes in the setting of IBR are 
lacking. Therefore, many patients who have had IBR receive PMRT to target volumes similar to 
conventional simulator-based whole breast irradiation. The aim of this paper is to describe 
delineation guidelines for PMRT after implant-based IBR based on a thorough understanding of 
the surgical procedures, disease stage, patterns of recurrence and radiation techniques. They are 






































































Breast cancer is the most common non-skin cancer in women worldwide. The vast majority of 
patients have non-metastatic disease at diagnosis [1]. The rates of mastectomy with an immediate 
breast reconstruction (IBR), mainly an implant/prosthesis-based reconstruction (IBR-i), as a 
surgical treatment for early breast cancer patients are increasing [2, 3].  
Indications for postmastectomy radiation therapy (PMRT) are based on tumour-related 
characteristics and other prognostic risk factors. Lately, the number of patients receiving PMRT 
[4](Frasier, et al. 2016)(Frasier, et al. 2016)(Frasier, et al. 2016) has increased based on evidence 
that PMRT for pN1 breast cancer patients treated with mastectomy and axillary dissection 
reduces recurrences and breast cancer mortality [4-6].  Although some studies have suggested 
that PMRT in the setting of reconstruction increases the relative rate of complications regardless 
of the type (implant or autologous) and the timing of reconstruction [7-9], fewer complications 
and better long-term cosmetic outcome have been reported when an autologous flap-based 
reconstruction was performed compared to IBR-i in combination with PMRT [7-10]. The IBR-i 
has ~ 2.64 times higher odds of complications (95% CI 1.77, 3.94, p<0.001) than autologous-
flap-based reconstruction. The rates of reconstruction failure in the setting of PMRT at two years 
was reported to be 18.7% among patients with IBR-i versus 1% in the autologous reconstruction 
group [10]. 
Radiation therapy (RT) in the setting of breast reconstruction is challenging. Surgical techniques 
for breast reconstruction continue to develop with the aim of improving cosmetic outcomes via 
pre or post-pectoral placement of the implant, or the use of an autologous-flap, lipofilling or 
synthetic coverage materials in conjunction with the implant [11]. However, little is known about 




































































and factors underpinning these outcomes after breast reconstruction and PMRT [2, 7, 9, 12, 13]. 
In addition, most studies of breast reconstruction and PMRT did not specify the influence of 
radiation techniques and dose-fractionation schedules used or the long-term oncological 
outcomes including patterns of recurrence [12-15].  
Current PMRT techniques used in the post-IBR setting are still often field-based rather than 
volume-based such that the target volume frequently includes the implant or reconstructed breast 
itself. The use of modern volume-based RT planning may reduce the dose to normal tissue and 
thereby treatment-related toxicity, without compromising target coverage [16].  
Our multidisciplinary initiative aims to define delineation guidelines for the clinical target 
volume (CTV) for PMRT in the setting of IBR-i and autologous IBR (IBR-a). This manuscript 
focuses on the setting of IBR-i, presenting the consensus guideline aiming to limit the CTV to 
clinically relevant volumes and thereby the risks of RT-related complications. 
 
Methods 
In February 2016 the challenges of PMRT in the setting of IBR were discussed at the Assisi 
Think-Tank Meeting on breast cancer [17]. In addition, development of the DBCG RT Recon 
Trial (ClinicalTrials.gov NCT03730922), a randomised study of the Danish Breast Cancer Group 
(DBCG) for patients who require PMRT and plan to have IBR-i as a first step of a delayed-
immediate breast reconstruction necessitated development of guidelines for target volume 
delineation. An international group of breast cancer experts (BVO, PP, OKP, LB, CC, IM) 




































































feasibility and dosimetric considerations using treatment planning CT scans of two patients who 
had an IBR-i [18]. 
In November 2017 a broader international multidisciplinary group of breast cancer experts 
including breast surgeons, plastic surgeons, radiation oncologists, and clinical oncologists 
(authors list) was invited to participate in the consensus guidelines development via the 
following steps: 
1) Between January and March 2017 the current practices for IBR-PMRT of the expert group 
were assessed via a multiple-choice web-questionnaire of 6 questions (Table 1).  
2) The expert group participated in a European Society of Radiation & Oncology (ESTRO)’s 
FALCON platform-based [19] CTV contouring exercise using four representative cases which 
comprised two IBR-i cases and two-IBR-a cases. The writers of the DBCG RT Recon Trial 
guidelines visually compared and discussed the CTVs contoured separately for the group 
involved in development of the DBCG delineation guidelines and the group of experts who were 
not involved. This was also done separately for the breast- and plastic surgeons and oncologists. 
Email correspondences among the participants regarding the challenges in contouring the CTVs 
were reviewed and discussed. 
3) The project was presented by PP at the 11
th
 European Breast Cancer Conference (EBCC11) in 
March 2018, and a panel discussion was conducted about potential factors associated with 
cosmetic outcomes in the setting of IBR and PMRT. This panel included three more 
representatives from our breast cancer expert team (FM, MJC, OKP). 
4) Sixteen expert team members met in a closed session at ESTRO 37 in April 2018 to discuss 




































































IBR-a; additional data required to complete the consensus guidelines especially for IBR-a; 
modification of the guidelines based on surgical data, disease stage, site of recurrence; and 
current practices. 
5) An open panel discussion chaired by BVO was held at ESTRO 37 in April 2018. The project 
was presented by PP [20] and OKP [21]. Input from the audience was taken into consideration in 
the consensus guidelines development. 
6) At all times, the expert group members communicated via email to resolve outstanding issues 
in guidelines development. The core group (BVO, PP, OKP) conducted teleconferences and 
face-to-face meetings to finalize the guidelines. 
7) The draft manuscript was written by the core group (BVO, PP, OKP), and reviewed and 
approved by all authors. The other expert group members are acknowledged in the manuscript. 
 
Results 
Group pre-work based on web-questionnaire  
According to the results of web-questionnaire (Table 1), most participants agreed that target 
volume delineation guidelines for IBR according to the surgical procedure can be applied in 
clinical practice once they are made available. 
 
Results of delineation exercise 
The visual comparison of the CTV contours between the different groups of contributors to the 




































































DBCG RT Recon Trial, half of the other radiation oncologists and one surgeon. While the other 
surgeon contoured a much smaller CTV, the other half of the radiation oncologists included the 
entire chest wall with the implant, similar to a conventional simulator-based treatment set up. 
 
Recommendations on target volume delineation for chest wall 
A sound understanding of the breast’s anatomy, regional lymphatics drainage patterns, disease 
stage, and procedures of breast surgery and IBR is essential to guide delineation of the 
CTVp_chest wall (i.e., p – primary). Detailed surgical and pathological reports are required. We 
recommend marking of scars and palpable/visible anatomical and surgical effects such as the 
borders of the surgical resection of subcutaneous, breast and fatty tissue. 
Although the skin is not part of the CTV, except in patients with a T4b, T4c and T4d breast 
cancer, the subcutaneous lymphatic plexus clearly is. During a total mastectomy the skin is 
pulled together and sutured, thereby reducing the size of the CTVp_chest wall compared to a 
CTVp_breast. The surface-reducing effect of mastectomy as described above is not the case 
when skin-sparing (with removal of nipple-areolar complex) or nipple-sparing (with preservation 
of skin and nipple-areolar complex) mastectomy is performed. These surgical approaches have 
gained popularity as initial reports have not shown a higher local recurrence rate than patients 
treated with skin-ablating mastectomy [22]. However, as more skin is preserved, it is likely that 
there will be more residual draining lymphatics and mammary glandular tissue [23], potentially 
resulting in an increase in local recurrence risk [23-25]. Moreover, uncertainty in defining the 
residual glandular tissue remains due to the limited data available [24, 26, 27]. The location of 
the residual glandular tissue varies in individual patients and depending on surgical procedure 




































































“axillary-tail” and in up to 22% of cases in the upper inner quadrant [23]. We strongly 
recommend that the borders of residual skin be determined in conjunction with the surgeon and 
marked before planning CT scanning. The CT scans should also be reviewed for residual tissue 
that is not evident on physical examination. 
 
Understanding the mammary lymphatic drainage pattern   
The lymphatics from the mammary region drain via the dermal plexus located within the 
subcutaneous tissues (Figure 2). The glandular tissue over the dorsal fascia of the breast is not 
connected to the major pectoral muscle, and hence, in the absence of tumour invasion the muscle 
is not part of the CTVp_chest wall. About three quarters of the lymphatics drains to the axillary 
nodes. The lymphatics may also drain into a connection along the borders of the glandular tissue 
and then around the edge of the major pectoral muscle into the interpectoral (Rotter’s) nodes 
(Figure 2) or through or between the pectoral muscles directly to the apical axillary nodes. 
Lymphatics may finally also drain alongside the penetrating blood vessels through the medial 
side of the major pectoral muscle into the internal mammary nodes. Thus, the deep lymphatic 
plexus (Figure 2, level 2-4) is part of the target volume in patients with more advanced breast 
cancer who should also be considered for internal mammary lymph node irradiation [28-30]. 
Target volumes for elective nodal irradiation should be contoured according to the ESTRO 
guidelines [31, 32]. 
 




































































The mastectomy procedure may vary according to oncological and aesthetic requirements. In 
general, the mammary gland is dissected from the skin envelope along the subcutaneous 
(Scarpa’s fascia) plane. The nipple areolar complex may or may not be preserved (see below).  
The gland is dissected off the pectoral muscle in the plane between the retro-mammary and pre-
pectoral fascia, preserving the fascia if oncologically appropriate.  
The implant (tissue expander or permanent implant) may be positioned pre or post to the major 
pectoral muscle: 
1) Posterior (dorsal) to the major pectoral muscle (retro-pectoral position). Additional 
materials e.g. de-epithelialized dermal flap, synthetic mesh or a bio-mesh of animal or 
human tissues (acellular dermal matrix - ADM) are most often used to provide complete 
coverage of the implant caudally of the pectoral muscle and to achieve the preferred 
breast shape (Figure 3A, B).  
2) Anterior (ventral) to the major pectoral muscle (pre-pectoral) directly into the skin 
pocket. The implant is secured in position with a mesh covering the largest part of the 
superficial surface of the implant (Figure 3C)  [33, 34]. 
After mastectomy, the CTVp_chest wall includes the residual subcutaneous glandular tissue and 
the subcutaneous lymphatics. The major pectoral muscle serves as the anatomical dorsal border 
for mastectomy. The muscle is typically described in anatomy textbooks as a thick fan-shaped 
muscle, originating from the medial half of the clavicle and ventral surface of the sternum as 
well as the cartilage of the 6th or 7th rib, and inserting into the bicipital groove and deltoid 
tuberosity of the humerus. Therefore, former CTVp_chest wall usually includes the levels from 
2nd to 6th rib in craniocaudal direction. However, according to the ESTRO guideline [31, 32], 




































































evaluating RT-planning CT-scans, anatomical aspects such as size (extent and thickness) of the 
major pectoral muscle and position of the breast varies among women, dependent on age, body 
mass index, patient’s fitness, etc. Therefore, in general most of the breast glandular tissue is 
positioned ventral to the major pectoral muscle, whilst a smaller more lateral part of glandular 
tissue is located ventral to the anterior serratus muscle and more caudally ventral to the ribs and 
intercostal muscles and in some patients, up to the ventral part of the external oblique abdominal 
muscle (Figure 4A, B). Consequently, per ESTRO recommendation for CTVp_chest wall 
delineation, the cranio-caudal borders should be defined by careful clinical examination of the 
patient with positioning of skin markers for the planning-CT (e.g., scars) and taking into account 
the position of the contralateral breast. It is not advisable to use the latter as a mere mirror 
because during mastectomy, both parts of the CTV are approximated, thereby reducing the 
surface of the target volume compared to the intact breast [31, 32]. The medial and lateral 
borders should be per ESTRO recommendations for chest wall delineation [31, 32]. 
Importantly, approximately 5-10% of the glandular tissue is retained after conventional total 
mastectomy [23]. It is essential to include residual glandular tissue within the CTVp_chest wall. 
 
CTVp_chest wall after IBR general 
Our recommendations for the CTVp_chest wall are based on the observation that most of the 
local recurrences after mastectomy occur at the level of the skin and subcutaneous tissue (range, 
72-100%), where most of the residual glandular tissues and draining lymphatics are found [35, 
36]. The second most common site of recurrence is within the pectoral muscle, especially nearby 
the primary tumour site (0-28%) [35, 36]. In general, the CTVp_chest wall is positioned ventral 




































































the pectoral muscle is advised, and in case of rib cage invasion the ribs/intercostal muscles 
should also be focally included in the CTV [32]. As IBR is generally not advised in these 
patients, the dorsal (posterior) border of the CTV in most cases will be on the ventral side of the 
major pectoral muscle or the ribs and intercostal muscles where no pectoral muscle was present 
before surgery [32]. In the case of a retro-pectoral implant, the surgeon generally detaches the 
caudal and medial insertion of the major pectoral muscle. If thereby the original position of the 
pectoral muscle cannot be clearly identified on the planning CT scan, the dorsal CTV border 
may be extended locally over the ventral side of the ribs [36, 37]. It is therefore strongly advised 
that the surgeon places clips to assist in the location of the primary tumour site and in the case of 
a retro-pectoral implant also of the pre-surgical insertion of the major pectoral muscle on the 
ribs. Delineation should preferably be undertaken in conjunction with the surgeon to 
individualise the CTVp_chest wall according to the primary tumour site and degree of tumour 
extension. 
 
CTVp_chest wall after IBR using post-pectoral implant (Figure 3A, B) 
If the dorsal fascia of the breast is not involved by cancer, the CTVp_chest wall for PMRT does 
not include the deep lymphatic plexus and therefore only includes the rim of tissue ventral to the 
major pectoral muscle and the implant, except at the medial, lateral and caudal borders where it 
may extend to the ventral side of the chest wall where it is not covered by the pre-surgical 
extension of the major pectoral muscle. Thus, the implant can be largely excluded from the 
CTVp_chest wall, while the parts of the chest wall surrounding the pectoral muscle around 
which the lymphatics flow should still be included (Figure 4A, B). As the pectoral muscle 




































































least partially in the CTV, meaning that the dorsal margin of the CTV would be at the ventral 
side of the implant.  
For patients with adverse factors and/or where the tumour was localised in areas within the 
breast close to the dorsal fascia that was not covered by the major pectoral muscle (mainly 
caudally located tumours that are often located adjacent to the intercostal muscles and ribs), only 
separated by the dorsal breast fascia, we recommend to delineate the tissue between the chest 
wall and the implant caudal from the pre-surgical position of the major pectoral muscle (ideally 
marked by surgical clips), which can be done as a separate dorsal CTV (Table 2; Figure 4B).  
 
CTVp_chest wall after IBR with pre-pectoral implant  
After IBR-i using a pre-pectoral positioned implant, the CTVp_chest wall is composed of 2 parts 
as the pre-pectoral volume is divided into 2 parts by the implant (Figure 3C): 
1) the ventral part between the skin and the implant, containing the subcutaneous lymphatic 
plexus and eventual residual glandular tissue (Figure 4C, red contour); 
2) the dorsal part between the implant and the pectoral muscle/chest wall, containing 
eventual residual glandular tissue (Figure 4C, blue contour): only to be included in case 
of the presence of adverse tumour factors (Table 2). 
 
Volumes to be delineated: summary 
The implant and the contralateral breast should be delineated using a planning-CT (Table 3). The 
transplanted tissues (skin; fat; muscle) and synthetic materials (implant, tissue expander, ADM) 




































































compromising the CTVp_chest wall coverage. Other OARs that should be delineated for 
treatment planning purposes include heart, lungs, liver, thyroid and, in case of axillary lymph 
node irradiation with a regional boost, the brachial plexus. 
 
Discussion 
Consensus-based guidelines on radiation target volume definition in patients with breast cancer 
treated with mastectomy and IBR are lacking. Most publications reporting on PMRT after 
immediate or other breast reconstruction do not provide sufficient details on target volume 
delineation and RT planning. The current paper provides a detailed delineation guideline for 
PMRT after IBR-i endorsed by a global multidisciplinary group of breast cancer experts. 
It is recommended that the guidelines be considered in the context of complete information about 
loco-regional disease staging (including staging pre and post primary systemic therapy if 
applicable); individual anatomical variations (e.g. chest wall thickness); location of potential 
residual glandular tissue in discussion with the surgical team; evaluation of the contralateral 
intact breast and the pectoral muscles on planning CT; and the surgical procedures.  
Multidisciplinary collaboration is essential; breast surgeons are important partners in contouring 
the appropriate CTVp_chest wall. Moreover, patients who are planned to have a mastectomy and 
IBR-i should be pre-operatively evaluated by both the surgeons and radiation oncologists or 
alternatively, discussed at multidisciplinary tumour board meetings.  
Selected patients with LABC may be considered for IBR. In these cases, the CTV, based on the 
general guidelines and discussions in a multidisciplinary team conference, should be if required 




































































tumour deposits. In any case that the tumour staging is unknown/unclear, we recommend to 
irradiate after IBR-i in a manner similar to conventional simulator-based RT approaches for 
preserved breast irradiation, thereby including the entire mastectomy site including the implant.  
If the skin is not part of the target volume, the ventral limit is conventionally 5 mm deep to the 
skin surface to include the subcutaneous lymphatics of the breast. However, this may not be 
possible due to the surgical procedure and the stretching of the remaining skin over the implant 
resulting in a thin rim of skin envelop, making it impossible to crop the CTVp_chest wall to 5 
mm below the skin surface. There is no high-level evidence to guide the use of bolus material to 
increase the skin dose in PMRT after IBR. In preparation of the DBCG RT Recon trial protocol, 
planning of two test cases using a tangential, forward planned field-in-field technique showed 
that there was 100% skin dose over most of the reconstructed breasts with 6 MV photons without 
a bolus, except medially and laterally corresponding to entry and exit of the beams. Due to the 
potentially superficial location of subcutaneous lymphatics, we do not recommend cropping of 
the CTVp_chest wall 5 mm from the skin surface but, depending on the software for dose 
calculation used, including the skin surface in the CTVp_chest wall without routinely using 
additional bolus to optimise inverse treatment plan calculations and DVH-evaluation of the dose 
distribution. 
After a mastectomy with IBR, identification of the tumour bed is complex and challenging due to 
manipulation of the tissue during reconstruction. Therefore, we do not recommend the use of a 
“tumour bed” boost, unless the surgeon has placed clips to mark anticipated and subsequently 
confirmed involved resection margins that cannot be removed surgically.  
The current guidelines are intended for target volume delineation after IBR-i. Development of 




































































the range of surgical procedures. This paper does not support one breast reconstruction procedure 
over the other.  
By using volume-based RT, we aim to reduce potential complications by tailoring the target 
volume to tissues at risk for recurrence. It is necessary that patients treated according to the 
current guidelines be carefully monitored in terms of long-term oncological safety, treatment 
toxicity and cosmetic outcome. Hence, we support initiatives of prospective databases, such as 
the INSPIRE prospective cohort study and the Mastectomy Reconstruction Outcome Consortium 
(MROC) [10] to evaluate patient outcomes after mastectomy and reconstruction. We also 
encourage centres to participate in clinical trials such as the DBCG RT Recon Trial or the 
Primary Radiotherapy And DIEP flAp Reconstruction Trial (PRADA) (NCT02771938) 
(https://clinicaltrials.gov/ct2/show/NCT02771938), and contribute data to the prospective cohort 
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DISCLAIMER 
ESTRO cannot endorse all statements or opinions made on the guidelines. Regardless of the 
vast professional knowledge and scientific expertise in the field of radiation oncology that 
ESTRO possesses, the Society cannot inspect all information to determine the truthfulness, 
accuracy, reliability, completeness or relevancy thereof. Under no circumstances will ESTRO 
be held liable for any decision taken or acted upon as a result of reliance on the content of the 
guidelines.  
The component information of the guidelines is not intended or implied to be a substitute for 
professional medical advice or medical care. The advice of a medical professional should 
always be sought prior to commencing any form of medical treatment. To this end, all 
component information contained within the guidelines is done so for solely educational and 
scientific purposes. ESTRO and all of its staff, agents and members disclaim any and all 
warranties and representations with regards to the information contained on the guidelines. 





- We present multidisciplinary consensus-based target volume definitions for chest wall 
irradiation after mastectomy with immediate breast reconstruction. 
- Practical guidelines for target volume contouring in case of a retro-pectoral as well as a pre-
pectoral implant are now available. 
- These guidelines allow anatomically risk-adapted radiation therapy planning, avoiding the 
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Table 1: Prework web-questionnaire  
Question Answers (# of participants) 
In your daily practice, in case of IBR irradiation do 
you delineate target volume of chest 
wall/reconstructed breast? 
a. “yes”, in most cases. Target volumes are used for treatment set-up.  (18) 
b. “yes”, in most cases, after virtual simulation to enable dose homogenization. (2) 
c. “no”, in most cases we irradiate the volume of the whole reconstruction breast (similar volumes 
like virtually simulated RT for breast in place). (8) 
 
In the affirmative, do you delineate the clinical 
target volume according to the surgical 
procedure? 
a. “yes”, in most cases. (15) 
b. “no”, the target volume is in general very similar. (9) 
c. “no”, the target volume is similar like for the breast in place. (1) 
 
In the affirmative, in which case do you find it 
easier to delineate the clinical target volume?  
 
a. In cases of IBR-i. (17)   
b. In both IBR-i and IBR-a. (6) 
c. None. (3) 
d. In cases of IBR-a. (0) 
What would be helpful to define the clinical target 
volume in cases of IBR? 
a. Detailed surgical and pathological report. (5) 
b. Delineating with the assistance of a breast surgeon. (1) 
c. Extensive marking of scars and palpable/visible surgical effects. (0) 
d. At least 2 of the above. (12) 
e.  a+b+c (8) 
f.   The clinical target volume should be the IBR (similar to virtual RT for breast in place) 
irrespective of the type of surgery performed. (3) 
Can volume delineation guidelines for IBR 
according to the surgical procedure be applied in 
the clinical practice? 
a. “yes”. (23) 
b. “no”, until data from clinical trials is available. (4) 
c. “no”, surgical procedures change significantly which might compromise oncological outcomes. 
(1) 
How many PMRT IBR cases you treat a year?  a. < 10 (7) 
b. 10-20 (7) 
c. > 20 (14) 
Table
RT – Radiation therapy; PMRT- Postmastectomy radiation therapy ; IBR-immediate breast reconstruction; IBR-i – implant-based; IBR-a – 
autologous tissue based. 
Table 2: Indications for including a volume posterior to the implant in the CTVp_chestwall: 
Partial inclusion in post-pectoral implant positioning: in case of the presence of adverse factors and/or if the tumour was localised in areas 
within the breast close to the dorsal fascia that was not covered by the initial position of the major pectoral muscle: separate volume (blue 
volume in fig 4B) 
Complete inclusion in pre-pectoral implant positioning: in case of the presence of adverse factors (blue in fig 4C) 
Adverse prognostic tumour characteristics include: 
 Large primary breast cancer (pT3) treated by mastectomy and IBR-i 
 Locally advanced breast cancer (LABC) with non-pathological complete response to primary systemic therapy 




Table 3: ESTRO delineation guidelines for the CTV in case of implant-based immediate breast reconstruction*. The ventral or superficial part of 
the CTVp_chestwall includes the space between the skin and the superficial sides of the pectoral muscles and the implant where not covered by 
muscle. The dorsal or deep part of the CTVp_chestwall is the virtual space between the dorsal side of the implant and the pectoral muscles or 
ribs and intercostal muscles where no muscle is present. While the ventral part is always part of the CTV, the dorsal part is only included 
depending on anatomical and tumour-related factors that are listed in table 2. 
Border per 
region 
CTV Retro-pectoral implant: CTV Pre-pectoral implant 
Cranial  Guided by palpable/visible signs, planning CT; if appropriate guided 
by the contralateral breast; maximally up to the caudal edge of the 
sterno-clavicular joint  
Guided by palpable/visible signs, planning CT; if appropriate 
guided by the contralateral breast; maximally up to the caudal 
edge of the sterno-clavicular joint  
Caudal Guided by palpable/visible signs; if appropriate guided by the 
contralateral breast 
Guided by palpable/visible signs; if appropriate guided by the 
contralateral breast 
Ventral 1. Ventral part: if possible, up to 3-5 mm under the skin surface;  
2. Dorsal part caudal from original insertion of pectoral muscle: 
the dorsal side of the implant. 
1) Ventral part: if possible up to 3-5 mm under the skin surface;  
2) Dorsal part: the dorsal side of the implant. 
Dorsal 1. Ventral part: major pectoral muscle or implant where no 
muscle; 
2. Dorsal part caudal from original insertion of pectoral muscle: 
ribs and intercostal muscles. 
** consider including the superficial part of the pectoral muscle if it 
is thin or in case of local invasion. 
1) Ventral part: ventral side of the implant.  
1) Dorsal part: ventral side of the pectoral muscles or ribs and 
intercostal muscles where no muscle is present. 
** consider including the superficial part of the pectoral muscle in 
case of local invasion  
Medial Guided by palpable/visible signs; if appropriate guided by the 
contralateral breast. Lateral to the medial perforating mammary 
vessels. 
Guided by palpable/visible signs; if appropriate guided by the 
contralateral breast. Lateral to the medial perforating mammary 
vessels. 
Lateral Guided by palpable/visible signs; if appropriate guided by the 
contralateral breast. Usually ventral to the mid-axillary line 
(important, location of most residual glandular tissue). Ventral to 
the lateral thoracic artery. 
Guided by palpable/visible signs; if appropriate guided by the 
contralateral breast. Usually ventral to the mid-axillary line 
(important, location of most residual glandular tissue). Ventral to 
the lateral thoracic artery. 
*Some of the CTV borders are as previously published in ESTRO guidelines on target volume delineation for elective radiation therapy of early 
stage breast cancer [21]. 
Table
Figure 1: CTV contouring of case with immediate breast reconstruction 
left using an implant. A: by writers of guideline of DBCG RT Recon Trial 
(n=5); B: by other radiation oncologists (n=18); C: by breast cancer 
surgeons (n=2).  
A B C 
Figure
Figure 2: Lymphatic draining pattern from the mammary region via the 
dermal plexus located within the subcutaneous tissues. 
Figure
Figure 3: Implant positioning. A: retropectoral with full coverage by the 
pectoral muscle; B: retropectoral with partial coverage by the pectoral 
muscle and supportive material in the lower part; C: prepectoral with 
full coverage by supportive material. 
Figure
Figure 4A: CTVp_chestwall with only a ventral part (red) in cases for 
whom only the subcutaneous lymphatic plexus should be irradiated. 
Pectoral muscles (yellow) and implant (green). 
Figure
Figure 4B: CTVp_chestwall with a ventral (red) and dorsal (blue) part in 
cases for whom the subcutaneous lymphatic plexus should be irradiated 
as well as the part of the chest wall that was initially not covered by the 
pectoral muscles (yellow). Retropectoral implant (green). 
Figure
Figure 4C: CTVp_chestwall with a ventral (red) and dorsal (blue) part in 
cases with a prepectoral implant (green). Pectoral muscles (yellow). 
Figure
